No Result
View All Result
SUBSCRIBE | NO FEES, NO PAYWALLS
MANAGE MY SUBSCRIPTION
NEWSLETTER
Corporate Compliance Insights
  • Home
  • About
    • About CCI
    • CCI Magazine
    • Writing for CCI
    • Career Connection
    • NEW: CCI Press – Book Publishing
    • Advertise With Us
  • Explore Topics
    • See All Articles
    • Compliance
    • Ethics
    • Risk
    • FCPA
    • Governance
    • Fraud
    • Internal Audit
    • HR Compliance
    • Cybersecurity
    • Data Privacy
    • Financial Services
    • Well-Being at Work
    • Leadership and Career
    • Opinion
  • Vendor News
  • Library
    • Download Whitepapers & Reports
    • Download eBooks
    • New: Living Your Best Compliance Life by Mary Shirley
    • New: Ethics and Compliance for Humans by Adam Balfour
    • 2021: Raise Your Game, Not Your Voice by Lentini-Walker & Tschida
    • CCI Press & Compliance Bookshelf
  • Podcasts
    • Great Women in Compliance
    • Unless: The Podcast (Hemma Lomax)
  • Research
  • Webinars
  • Events
  • Subscribe
Jump to a Section
  • At the Office
    • Ethics
    • HR Compliance
    • Leadership & Career
    • Well-Being at Work
  • Compliance & Risk
    • Compliance
    • FCPA
    • Fraud
    • Risk
  • Finserv & Audit
    • Financial Services
    • Internal Audit
  • Governance
    • ESG
    • Getting Governance Right
  • Infosec
    • Cybersecurity
    • Data Privacy
  • Opinion
    • Adam Balfour
    • Jim DeLoach
    • Mary Shirley
    • Yan Tougas
No Result
View All Result
Corporate Compliance Insights
Home Featured

Private Equity in DOJ’s Line of Fire

by Lorinda Holloway
November 14, 2018
in Featured, Fraud
lying businessman holding cash

Liability Under the False Claims Act

The government can be slow, but it catches up. The DOJ and whistleblowers have recently targeted private equity firms and individuals in False Claims Act cases based on officer and director roles and/or involvement in management. Because the foundations of health care compliance and private equity business goals frequently clash, investors are wise to evaluate their level of involvement and jump on the compliance bus to avoid getting run over.

Health care is a heavily regulated industry and can make for a risky investment if the business in which in a private equity sponsor is investing has significant compliance problems.

A potentially costly risk is civil or criminal charges brought by the government or a private citizen on behalf of the government (a “relator”) under the False Claims Act (the FCA).[1] The FCA imposes liability on individuals and entities that knowingly present or cause to be presented a false claim for payment or fail to promptly return an overpayment it knew or should have known it received.

With triple damages, a range of steep penalties per claim and potential criminal exposure in play, FCA risk is no joke. For the private equity investor, careful pre-acquisition due diligence to detect such potential risk is truly no longer enough if the private equity investor plans to cross the executive, board room or management threshold, which investors often do.

FCA Cases Against PE Investors in 2018

The following two FCA cases were filed against private equity investors in 2018. The cases remain pending with many FCA development followers watching closely.

  1. In Florida, two former pharmacy employees filed an FCA suit against a private equity sponsor, the fund’s portfolio pharmacy and two pharmacy executives for their involvement in an alleged kickback scheme.[2] The government intervened, alleging that the fund had a controlling interest in the pharmacy and that two fund representatives were actively involved as pharmacy board members and officers and that they even played an active role in managing the pharmacy. While awaiting a court ruling in this case, the government recently filed a notice pointing the court to yet another case (discussed below) where equity investors are also named and did not get off the hook at the motion to dismiss stage.
  2. A whistleblower and the Commonwealth of Massachusetts filed an FCA suit against a mental health care operator, its former CEO and a private equity investor, alleging Medicaid was billed for services provided by unlicensed and unsupervised employees.[3] The complaint alleges that the officers and members of the portfolio company and the private equity investor overlapped, and board members were heavily involved in operational decisions, including contract approval, strategic planning, budgeting and earnings issues. In denying the equity investors’ motion to dismiss — wherein the investor defendants argued there was no explanation of how they directly caused the submission of false claims — the court noted that the FCA does not always require an affirmative act to impose liability. Rather, an investor can be liable where the submission of false claims by another entity was the foreseeable result of a business practice, and in this case the complaint adequately alleged that the private equity fund members and principals formed a majority of the operator’s board, were directly involved in operations and had been advised of the noncompliance issues.

Therefore, depending on one’s tolerance for risk, private equity firms and their representatives are wise to evaluate just how involved they plan to be in the portfolio company. Consider the value versus risk of:

  • board or officer roles,
  • board control by equity investors and
  • involvement in operations or management.

Avoiding such involvement is no guarantee of an investment free of FCA risk, but given the developing case law, such involvement will increase the likelihood of being named in any FCA case filed against the portfolio company. Being named in an FCA suit can be terribly distracting, unproductive and costly, even if there is ultimately no merit to the claim. Therefore, weighing the benefits of hands-on involvement at the executive level, board level and/or management level is important.

If on balance an equity investor decides the value of direct involvement is worth the risk, then compliance and all that a robust compliance program entails must be a priority for that investor. This means ensuring that the portfolio company’s compliance policies are in place, including policy of no retaliation against whistleblowers, compliance trainings are happening, audits are proactively conducted, exclusion checks on employees are run, Anti-kickback and Stark compliance, a compliance hotline is in place and the list goes on.

Of course, effective compliance is not likely to happen if the private equity investor is only focused on the bottom line and is not in lock step with the portfolio company in all manner of compliance. Indeed, these two interests often naturally collide.


[1] 31 U.S.C. § 3729 et seq.

[2] U.S. ex rel. Medrano v. Diabetic Care, Rx, LLC, et al., Case No. 15-cv-62617 (S.D. Fla. 2018).

[3] U.S. ex rel. Martino-Fleming v. South Bay Mental Health Center, Inc., et al., Civil Action No. 15-13065 (D. Mass. 2018).


Tags: DOJDue DiligenceFalse Claims Act (FCA)
Previous Post

Why 2019 Could Be a Challenging Year for Internal Audit

Next Post

TRACE: Lisa Osofsky: New Director of the SFO

Lorinda Holloway

Lorinda Holloway

Lorinda Holloway is the Managing Partner of Husch Blackwell, LLP’s Austin office and a partner in the firm’s Healthcare, Life Sciences & Education group. Lorinda represents and advises health care providers and educational institutions on compliance and risk management, defense of government investigations, litigation and trial. She has represented numerous entities and individuals in False Claims Act and Texas Medicaid Fraud Prevention Act investigations and litigation, as well as in all manner of business disputes in state and federal court.

Related Posts

doj sign front

Assessing the Business Risks of the Trump Administration’s ‘Total Elimination’ Strategy

by José Cortina and Jennifer Christian
May 20, 2025

As cartels increasingly participate in mainstream economic activities, traditional due diligence practices become inadequate to address new material support risks

drug cartel soldier camo

Leveraging Human Rights Frameworks to Combat Emerging Cartel Risks

by Nate Lankford, Matteson Ellis and Nisha Sawhney-Murkett
May 19, 2025

As enforcement priorities shift to cartels and foreign terrorist organizations, established human rights processes can identify and mitigate emerging legal...

doj sign and sculpture

DOJ’s New CEP Proposes Guaranteed Declination for Some Self-Reporters

by Jennifer L. Gaskin
May 13, 2025

The Trump Administration continues reshaping its approach to corporate crime, with the DOJ issuing major revisions of its corporate enforcement...

doj building sign with flags

‘Reasonable Steps’: What the DOJ Expects From Your Bulk Data Transfer Compliance Program

by Alexandra P. Moylan, Alisa L. Chestler and Michael J. Halaiko
May 5, 2025

Sample provisions offer blueprint for compliant data brokerage with foreign entities

Next Post
logo for serious fraud office

TRACE: Lisa Osofsky: New Director of the SFO

No Result
View All Result

Privacy Policy | AI Policy

Founded in 2010, CCI is the web’s premier global independent news source for compliance, ethics, risk and information security. 

Got a news tip? Get in touch. Want a weekly round-up in your inbox? Sign up for free. No subscription fees, no paywalls. 

Follow Us

Browse Topics:

  • CCI Press
  • Compliance
  • Compliance Podcasts
  • Cybersecurity
  • Data Privacy
  • eBooks Published by CCI
  • Ethics
  • FCPA
  • Featured
  • Financial Services
  • Fraud
  • Governance
  • GRC Vendor News
  • HR Compliance
  • Internal Audit
  • Leadership and Career
  • On Demand Webinars
  • Opinion
  • Research
  • Resource Library
  • Risk
  • Uncategorized
  • Videos
  • Webinars
  • Well-Being
  • Whitepapers

© 2025 Corporate Compliance Insights

Welcome to CCI. This site uses cookies. Please click OK to accept. Privacy Policy
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT
No Result
View All Result
  • Home
  • About
    • About CCI
    • CCI Magazine
    • Writing for CCI
    • Career Connection
    • NEW: CCI Press – Book Publishing
    • Advertise With Us
  • Explore Topics
    • See All Articles
    • Compliance
    • Ethics
    • Risk
    • FCPA
    • Governance
    • Fraud
    • Internal Audit
    • HR Compliance
    • Cybersecurity
    • Data Privacy
    • Financial Services
    • Well-Being at Work
    • Leadership and Career
    • Opinion
  • Vendor News
  • Library
    • Download Whitepapers & Reports
    • Download eBooks
    • New: Living Your Best Compliance Life by Mary Shirley
    • New: Ethics and Compliance for Humans by Adam Balfour
    • 2021: Raise Your Game, Not Your Voice by Lentini-Walker & Tschida
    • CCI Press & Compliance Bookshelf
  • Podcasts
    • Great Women in Compliance
    • Unless: The Podcast (Hemma Lomax)
  • Research
  • Webinars
  • Events
  • Subscribe

© 2025 Corporate Compliance Insights